Free Trial

Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis

$66.54
+0.92 (+1.40%)
(As of 05/29/2024 ET)
Today's Range
$64.72
$67.07
50-Day Range
$64.76
$79.84
52-Week Range
$45.50
$84.89
Volume
766,722 shs
Average Volume
912,879 shs
Market Capitalization
$7.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.17

Intra-Cellular Therapies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
35.5% Upside
$90.17 Price Target
Short Interest
Bearish
4.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
0.88mentions of Intra-Cellular Therapies in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$6.50 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.53) to $0.93 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.52 out of 5 stars

Medical Sector

105th out of 932 stocks

Pharmaceutical Preparations Industry

38th out of 437 stocks

ITCI stock logo

About Intra-Cellular Therapies Stock (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI Stock Price History

ITCI Stock News Headlines

ITCI Aug 2024 65.000 put
Intra-Cellular Therapies Inc
See More Headlines
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
5/29/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ITCI
Employees
610
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$90.17
High Stock Price Target
$120.00
Low Stock Price Target
$62.00
Potential Upside/Downside
+35.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-139,670,000.00
Pretax Margin
-21.38%

Debt

Sales & Book Value

Annual Sales
$464.37 million
Book Value
$5.68 per share

Miscellaneous

Free Float
101,985,000
Market Cap
$7.02 billion
Optionable
Optionable
Beta
1.01
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Sharon Mates Ph.D. (Age 71)
    Co-Founder, Chairman & CEO
    Comp: $2.23M
  • Mr. Michael I. Halstead J.D. (Age 51)
    President
    Comp: $983.65k
  • Dr. Suresh K. Durgam M.D. (Age 55)
    Executive VP & Chief Medical Officer
    Comp: $961.84k
  • Mr. Mark NeumannMr. Mark Neumann (Age 61)
    EVP & Chief Commercial Officer
    Comp: $998.36k
  • Dr. Robert E. Davis Ph.D. (Age 73)
    Senior VP & Chief Scientific Officer
    Comp: $646.12k
  • Mr. Juan Fernando Sanchez (Age 53)
    Vice President of Corporate Communications & Investor Relations
    Comp: $296.75k
  • Ms. Karen Patruno Sheehy Esq. (Age 62)
    Senior VP & Chief Compliance Officer
  • Dr. Michael Olchaskey
    Senior VP & Head of Regulatory Affairs
  • Mr. John A. Bardi
    Senior VP of Market Access, Policy & Government Affairs
  • Dr. Willie R. Earley M.D.
    Senior VP & Head of Clinical Development

ITCI Stock Analysis - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ITCI shares.
View ITCI analyst ratings
or view top-rated stocks.

What is Intra-Cellular Therapies' stock price target for 2024?

10 brokers have issued 12 month price objectives for Intra-Cellular Therapies' shares. Their ITCI share price targets range from $62.00 to $120.00. On average, they anticipate the company's share price to reach $90.17 in the next year. This suggests a possible upside of 35.5% from the stock's current price.
View analysts price targets for ITCI
or view top-rated stocks among Wall Street analysts.

How have ITCI shares performed in 2024?

Intra-Cellular Therapies' stock was trading at $71.62 at the start of the year. Since then, ITCI stock has decreased by 7.1% and is now trading at $66.54.
View the best growth stocks for 2024 here
.

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a increase in short interest in May. As of May 15th, there was short interest totaling 4,550,000 shares, an increase of 24.0% from the April 30th total of 3,670,000 shares. Based on an average trading volume of 946,300 shares, the days-to-cover ratio is presently 4.8 days.
View Intra-Cellular Therapies' Short Interest
.

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our ITCI earnings forecast
.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) posted its quarterly earnings data on Tuesday, May, 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.15. The biopharmaceutical company had revenue of $144.90 million for the quarter, compared to the consensus estimate of $141.41 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 18.49% and a negative net margin of 21.57%. The firm's revenue was up 52.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.46) earnings per share.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.53%), Wasatch Advisors LP (3.98%), Bellevue Group AG (2.67%), Avoro Capital Advisors LLC (2.34%), Clearbridge Investments LLC (1.65%) and Price T Rowe Associates Inc. MD (1.14%). Insiders that own company stock include Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates, Suresh K Durgam and Suresh K Durgam.
View institutional ownership trends
.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ITCI) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners